Porcine reproductive and respiratory syndrome virus (PRRSV) is an important pathogen of Porcine species which causes an estimated annual loss of more than 600 million dollars to the swine production industry in the United States alone (<http://nationalhogfarmer.com> August 17, 2011). The emergence of PRRSV as a pathogen was first observed in the 1980s and is currently a global epizootic ([@b0055]). The virus belongs to the order *Nidovirales*, family *Arteriviridae* and is characterized by positive strand RNA genome of approximately 15 kb (kilobases) and is enveloped. The PRRSV viral genomic RNA is capped and polyadenylated. The virus has been classified into two major strains, the Type I (European) and Type II (North American) ([@b0080]). The structural proteins of the virus are encoded from the distal third of the viral genome and are transcribed as sub-genomic mRNAs. The non-structural proteins take up the proximal two thirds of the viral genome and are synthesized as a shorter and a longer polyprotein, which are then processed into smaller proteins consisting of a variety of enzymes, such as proteases, RNA polymerases and RNA helicases. The non-structural proteins are shown to suppress the induction of host type I interferon genes and other cytokines ([@b0010], [@b0140]). The PRRSV is estimated to have a high rate of evolution of 3.29 × 10^−3^ substitutions per nucleotide site per year and new strains frequently appear in the field ([@b0095]).

The currently available inactivated and modified live vaccines are inadequate to eradicate the virus and do not provide complete immunity from infection ([@b0055]). Modified live vaccine PRRSV strains are also characterized by the shedding of the virus from vaccinated animals, which often revert to virulent strains ([@b0055], [@b0100]). Since the global PRRSV epizootic in pigs is not completely amenable to immunological intervention, a pharmacological intervention might be a valuable alternative or additional control measure. For PRRSV, past studies in cell culture models have revealed only few compounds displaying antiviral activity (see [Table 1](#t0005){ref-type="table"} ). In general, natural compounds constitute a major source of effective pharmacological agents including, artemisinin, anti tumor alkaloids, salicylates, opiates, etc. ([@b0060]). Therefore, we evaluated a commercially available library (Screen-Well™ Natural Product Library, Enzo life sciences) of 502 purified natural compounds for their activity against PRRSV infection and replication. To this end, we established a high-throughput screening method.Table 1A list of compounds in the published literature known to inhibit PRRSV replication and IC~50~ values for those estimated. NP -- not published.CompoundIC~50~Reference*Macrolide antibiotic*Bafilomycin∼0.2 μM[@b0040]  *Cellular ion transport targeting agents*VerapamilNP[@b0040]Amantadine\<0.2 μMPyrithioneNP[@b0110]  *Endosomal acidification blockers*Ammonium chloride\<0.5 mMChloroquinone\>6 μMMonensinNP  *Plant derived lectins*Indigowoad root polysaccharideNP[@b0120]Hippeastrum hybrid agglutinin\>2 μM*Galanthus nivalis* agglutinin\>2 μM*Cymbidium* sp. agglutininNP*Urtica dioica* agglutinin4.8 ± 3.2 μM  *Non-plant derived lectins*Pradimicin-A\>120 μM[@b0120]Cyanovirin-NNP  *ChelatorN*-acetylpenicillamineNP[@b0030]

An immunofluorescence assay (IFA) based high-throughput screening platform in a 384 well format to detect viral replication was established utilizing MARC-145 cells permissive to PRRSV infection. The viral proteins were detected using a highly specific monoclonal antibody against the nucleocapsid protein (ORF7) of the PRRSV (Clone 5H2; in-house produced). After empirical optimization, the assay was performed by seeding 1000 cells per well, infected at a multiplicity of infection (MOI) of 10 at the time of seeding. The antiviral effect was evaluated at 48 h post-infection by fixing the cells with 4% paraformaldehyde. We included mock-infected cells and PRRSV-infected cells with additional 1 μM of mycophenolic acid (MPA), a de novo purine synthesis inhibitor ([@b0090]), as negative and positive controls, respectively, for virus inhibition of replication. For the immunofluorescence assay, the primary mouse monoclonal antibody from hybridoma supernatant was used undiluted and the secondary donkey anti-mouse immunoglobulins antibody labeled with Alexa Fluor 546 (stock 2 μg/μL) was used at a dilution of 1:500 in PBS--Tween (0.1%). The primary and secondary antibodies were stocked in bulk quantities and aliquots of these stocks were used consistently throughout the studies. Following the antibody staining, the cell nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). The assay results were machine read with Cellomics® scanner, measuring the intensities of DAPI (indicating the nuclei of cells) and Alexa Fluor 543 (indicating the virus infection of cells). The percentage of infected cells was determined from this assay. The assay showed a *Z*-score of 0.53, when the PRRSV infected and infected cells with 1 μM MPA were compared, which validates the assay as highly reliable. Utilizing the assay, the compounds in the natural product library were screened for their ability to inhibit viral entry or/and replication by adding 10 μM the compound in DMSO (final concentration of 0.1%) to the cell plus virus mixture at the time of seeding. Mock-infected cells, infected cells, infected cells with 1 μM MPA and infected cells with 0.1% DMSO were used as controls. The compounds which caused a decrease of the DAPI intensity of treated cells to less than 70% of that of infected cells with only 0.1% DMSO were considered toxic to the cells and excluded from further analysis. The screening was repeated twice and we identified 19 compounds which inhibited the virus replication to less than 50% at a 10 μM concentration, as observed by IFA signal intensity, without adversely affecting the host cells ([Table 2](#t0010){ref-type="table"} ).Table 2The list of the 19 compounds found to inhibit the PRRSV replication at 10 μM concentration to less than 50% as observed by IFA signal intensity without decreasing of the DAPI intensity of treated cells to less than 70%. Con -- control inhibitor MPA.No.CompoundPercent viral signal compared to 0.1% DMSO treated infected cellsPercent DAPI signal (nuclei) compared to 0.1% DMSO treated infected cellsConcentration (μM)Concentration (μM)1010.11010.11Antimycin A123----81----2Bufalin[b](#tblfn2){ref-type="table-fn"}02177894963Catechin hydrate (+)-1892969195964Cepharanthine[b](#tblfn2){ref-type="table-fn"}2186888995955Cinobufagin[a](#tblfn1){ref-type="table-fn"}34----86----6Coumermycin A11974818294957Cryptotanshinone1685888696968Cycloheximide7----72----9Cyclopiazonic acid[b](#tblfn2){ref-type="table-fn"}1478868394961012-Deoxyphorbol 13-phenylacetate 20-acetate043689949511Dicoumarol36----89----12Digitoxin[a](#tblfn1){ref-type="table-fn"}12----84----13Gitoxigenin[a](#tblfn1){ref-type="table-fn"}11----85----14Harmaline41----86----15Hydrastine, [d]{.smallcaps}-β-24949879979716Hypocrellin B31----73----17Ouabain (−)-[a](#tblfn1){ref-type="table-fn"}00281939618Strophanthidin acetate[a](#tblfn1){ref-type="table-fn"}27----77----19Valinomycin001839596ConMycophenolic acid01276389696[^1][^2]

The compound library used for screening comprises of several classes of natural compounds; glycosides, terpenoids, coumarins, isoflavones, peptolides, alkaloids, flavones, macrolides, etc. The compounds belonging to the glycosides (known for their action on cardiac system) and cardio-active steroids were found in higher frequency to inhibit the viral replication in the assay. Of the identified 19 inhibitors, five were the glycosides and two were cardio-active steroids. These compounds share a similar mode of action on the ion channels in cells. Whether these compounds act on the cellular mechanisms and indirectly affect the virus or act directly on a viral component or mechanism is to be determined. The most likely viral target for these compounds could be the viral porin on the PRRSV envelope formed by the multimerization of the small envelope protein (ORF2b) ([@b0050]). Amantadine, known to block the M2 ion channel of the Influenza A, also blocks the PRRSV ORF2b porin ([@b0050]). Other compounds that inhibited the PRRSV included fungal metabolites and flavones. Subsequently, we selected ten compounds ([Table 3](#t0015){ref-type="table"} ), considering presence of known related pharmacological compounds and their biological effects. Compounds such as Cycloheximide, Dicoumarol and Harmaline, were not selected from the panel of 19 due to known undesirable biological activity profile. The toxicity effect of the selected ten compounds on MARC-145 cells was analyzed using alamar blue test (Invitrogen) by following the manufacturer's instructions. The alamar blue fluorescence of the infected cells treated with the compounds was not less than 70% of the untreated infected cells and correlated with the DAPI fluorescence intensities estimated previously (data not shown). The inhibitory effect of these compounds were evaluated using the signal intensity in IFA assay, as described earlier, at 0.1, 1 and 8 μM concentrations of each compound ([Table 2](#t0010){ref-type="table"}), by adding the compounds to the virus and cells at the time of seeding. The treatments were performed in triplicates and the experiment was performed twice.Table 3The list of 10 compounds selected for secondary assays, to estimate their efficacy to inhibit PRRSV at doses of 0.1, 1 and 8 μM concentration.No.CompoundKnown pharmacological action1BufalinCardiac glycoside with antiviral activity ([@b0020]).2Catechin hydrate, (+)-Flavonoid, anti-oxidant, cyclo-oxygenase inhibitor, anti inflammatory ([@b0045]).3CepharanthineAn alkaloid with antiviral activity against SARS CoV; anti-inflammatory, inhibits lipooxygenase ([@b0005], [@b0135]).4Coumermycin A1Novobiocin related antibiotic with antiviral activity ([@b0065]).5CryptotanshinoneA herb derived tanshinone that blocks Signal transducer and activator of transcription 3 (STAT3) dimerization and inhibits cytokine production by immune cells ([@b0035], [@b0085]).6Cyclopiazonic acidA fungal metabolite that acts on endoplasmic reticulum resident Ca^2+^ ATPase and mediates activation of NFkB, a key component of immune cell signaling ([@b0130]).712-Deoxyphorbol 13-phenylacetate 20-acetateA phorbol ester that activates PKCβ, and mimics IFN mediated signaling ([@b0075]).8Hydrastine, [d]{.smallcaps}-β-An alkaloid anti-inflammatory agent; inhibits cytochrome P450 mediated oxidation ([@b0070]).9Ouabain (−)-Cardiac glycoside with antiviral activity ([@b0105]).10ValinomycinA dodeca-depsipeptide antibiotic, anti inflammatory, lipo-oxygenase inhibitor. Known to be a potent antiviral agent against Severe Acute Respiratory Syndrome Corona virus (SARS CoV) ([@b0025], [@b0125]).

All the ten compounds inhibited the virus replication at 8 μM concentration. Only four of the compounds were inhibitory at 1 μM or sub-micro molar concentrations; 12-deoxyphorbol 13-phenylacetate 20-acetate (dPPA), ouabain, valinomycin and bufalin. The representative images of infection are shown in [Fig. 1](#f0005){ref-type="fig"} . Interestingly, the dPPA is known to activate the PKCβ and stimulate interferon signaling. Ouabain and bufalin are known to act on the cardiac system by affecting the ion channels. Further, bufalin perturbs signaling mediated by STAT3. Valinomycin, a dodecadepsipeptide antibiotic, is a potassium ionophore. Previous studies have shown that valinomycin has a potent antiviral activity against severe acute respiratory syndrome corona virus (SARS CoV), another important Nidovirus ([@b0125]). We estimated the 50% inhibitory concentrations (IC~50~) for the inhibition of viral replication of the four compounds as described earlier ([@b0125]). The IC~50~ values derived by curve fitting of mean of percent infected cells in triplicates observed by IFA at 8, 1, 0.1, 0.01, 0.001 and 0.0001 μM concentrations of the inhibitors, from three independent experiments. The IC~50~ were well below 1 μM ([Table 4](#t0020){ref-type="table"} ) for all the four compounds.Fig. 112-Deoxyphorbol 13 phenylacetate 20 acetate, ouabain, valinomycin and bufalin exhibited inhibition of the PRRSV replication at micro-molar or sub-micro-molar concentrations. Viral replication in the presence of 8, 1, 0.1 μM of the above compounds was examined by IFA. Nuclei -- DAPI staining (blue); PRRSV protein ORF7 staining (red). MPA -- mycophenolic acid as a positive control inhibitor. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Table 4The estimated IC~50~ of the four compounds with the highest inhibitory activity.CompoundIC~50~ (±standard deviation)Bufalin52 nM (±3.8)12-Deoxyphorbol 13-phenylacetate 20-acetate118 nM (±8.4)Ouabain (−)-41 nM (±3.2)Valinomycin24 nM (+4.6)

We next evaluated if these four compounds acted on the binding and entry steps of the virus or during the replication process. MARC-145 cells were incubated with each of the compounds (1 μM) for 1 h prior to the addition of the virus at an MOI of 10 and subsequently the cells were incubated at 37 °C for 2 h. After which, the cells were washed thrice with phosphate buffered saline (PBS) and the cells were incubated in fresh media and fixed after 48 h. The results showed that identified four compounds do not block the binding and entry of the virus, but act during the subsequent replication process. Next, the cells were infected with the virus at an MOI of 10 and incubated with compounds (1 μM) from 0, 2 or 8 h post infection (hpi) and fixed at 48 hpi. The IFA signal quantification results ([Table 5](#t0025){ref-type="table"} ) showed that virus replication was almost completely inhibited by all the four compounds when added 2 hpi. However, when added at 8 hpi, dPPA decreased the viral signal only by 30% while the other three compounds almost completely inhibited the signal. The results show that dPPA inhibits the virus replication by acting on the early event in virus--cell interaction. The dPPA is known to mimic the cellular interferon signaling ([@b0075]), and possibly acts by augmenting the interferon mediated virus suppression. The other three compounds are known act on ion channels and could have a different mode of action. These compounds which are inhibitory even when added in the later stages of infection could have a better value in the in vivo inhibition of the virus. Further detailed analysis needs to be performed to identify their exact mode of action. Next the inhibitory activities of the compounds were tested in a rapid cytopathic effect (CPE) inhibition assay adapted from [@b0015]. The MARC145 cells were infected with PRRS virus at an MOI of 10 with or without the above four compounds (at 8, 1 and 0.1 μM concentration) and examined for CPE at 72 h post infection. The untreated infected cells showed extensive CPE at 72 hpi. At 8 and 1 μM concentrations, all of the four compounds completely inhibited observable CPE at 72 hpi. However, at 0.1 μM concentration dPPA showed mild CPE. The CPE inhibition assay showed that compounds were effective in inhibiting the virus induced cellular pathology.Table 5Effect of time of addition after infection on the inhibition of virus replication of the compounds at 1 μM. hpi -- hours post infection.CompoundPercent viral signal compared to 0.1% DMSO treated infected cells when compounds were added at indicated hpi028Bufalin03712-Deoxyphorbol 13-phenylacetate 20-acetate0268Ouabain (−)-004Valinomycin015Mycophenolic acid0316

Apart from these four compounds, the other compounds from the original 19 identified to inhibit PRRSV at 10 μM concentration or the analogs of these compounds could have a better profile of activity in other cell culture models for PRRSV replication or in in vivo studies. However, as PRRSV infection could not be successfully modeled in a laboratory animal, the in vivo studies will have to be performed in pigs or piglets. Considering the rapid evolution rate of PRRSV ([@b0055], [@b0095]), the eradication of the virus cannot be achieved only by immunological intervention, which is the trend observed in the field so far. Therefore, a therapeutic intervention with pharmacological agents inhibiting virus replication could represent a valuable alternative or additional tool against PRRSV. For the latter, a combined immunological and pharmacological intervention could decrease the risk of the emergence of resistant strains as well. In conclusion, we here identified several natural compounds displaying potent antiviral activity, providing a basis for further research for pharmacological agents against PRRSV.

[^1]: Cardiac glycosides.

[^2]: Compounds known to act on ion channels.
